title: Phenylbutyl isoselenocyanate modulates phase I and II enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced DNA adducts in mice.
abstract: Lung cancer remains one of the most preventable forms of cancer with about 90% of cases attributed to cigarette smoking. Over the years, the development of chemopreventive agents that could inhibit, delay, or reverse the lung carcinogenesis process has been an active field of research, however, without much attainment. Through extensive structure-activity relationship studies, we recently identified a novel agent phenylbutyl isoselenocyanate (ISC-4), designed on the basis of naturally occurring isothiocyanates well known for their lung cancer prevention properties, as a potential chemopreventive agent. In this study, we used A/J mice to evaluate the lung cancer chemopreventive potential of ISC-4. A single intragastric dose of 1.25 μmol ISC-4 resulted in a time-dependent increase of selenium levels in serum, liver, and lung, suggesting that ISC-4 is orally bioavailable, a key requirement for a chemopreventive agent. This dose also resulted in a time-dependent inhibition of microsomal cytochrome P450 (Cyp450) activity and delayed increases in phase II UDP-glucuronyl transferase (Ugt) and glutathione-S-transferase (Gst) activity. ISC-4 was able to induce mRNA expression of Cyp, Ugt, and Gst enzyme isoforms in liver, but in lung, it inhibited Cyp isoforms while inducing Ugt and Gst isoforms. In addition, ISC-4 effectively inhibited methyl-DNA adduct formation in mice fed diet supplemented with ISC-4 for two weeks and then treated with the tobacco procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. These results suggest that ISC-4 is a strong candidate for development as a chemopreventive agent.
authors.affiliation: Penn State Milton S. Hershey Medical Center, Department of Pharmacology, Penn State Hershey Cancer Institute, Penn State Hershey College of Medicine, CH72, 500 University Drive, Hershey, PA 17033, USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Crampsie
authors.forename: Nathan
authors.initials: N
authors.lastname: Jones
authors.forename: Arunangshu
authors.initials: A
authors.lastname: Das
authors.forename: Cesar
authors.initials: C
authors.lastname: Aliaga
authors.forename: Dhimant
authors.initials: D
authors.lastname: Desai
authors.forename: Philip
authors.initials: P
authors.lastname: Lazarus
authors.forename: Shantu
authors.initials: S
authors.lastname: Amin
authors.forename: Arun K
authors.initials: AK
authors.lastname: Sharma
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015153:Blotting, Western; D002273:Carcinogens / Q000008:administration & dosage / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D003600:Cytosol / Q000187:drug effects / Q000201:enzymology; D018736:DNA Adducts / Q000187:drug effects*; D005260:Female; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism*; D005982:Glutathione Transferase / Q000235:genetics / Q000378:metabolism*; D008168:Lung / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D008805:Mice, Inbred A; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D009602:Nitrosamines / Q000008:administration & dosage / Q000494:pharmacology*; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D002273:Carcinogens; D018736:DNA Adducts; C561852:ISC-4 compound; D009602:Nitrosamines; D016566:Organoselenium Compounds; D012333:RNA, Messenger; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; D003577:Cytochrome P-450 Enzyme System; D014453:Glucuronosyltransferase; D005982:Glutathione Transferase; D051057:Proto-Oncogene Proteins c-akt